ReviewCirculation research2026
Kidney-Vascular Metabolic Crosstalk: Altered Lipoproteins in CKD.
Review in Circulation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Cardiovascular disease and chronic kidney disease are highly interconnected, with declining kidney function markedly increasing cardiovascular risk. Chronic kidney disease profoundly disrupts lipoprotein metabolism, leading to qualitative and quantitative alterations that modify lipoprotein composition, function, and clearance. These changes influence not only arterial wall cells, promoting vascular inflammation, smooth muscle cell dysfunction, and macrophage inflammation, as well as atherosclerosis, but also renal cell populations, potentially exacerbating kidney injury and accelerating disease progression. In this review, we examine mechanisms by which kidney dysfunction contributes to heightened cardiovascular risk. We place particular emphasis on altered lipoprotein metabolism as a central mediator linking vascular and renal pathology in chronic kidney disease, highlighting how dysfunctional lipoproteins may drive parallel injury responses in both the artery wall and the kidney.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.